OncoMatch/Clinical Trials/NCT06584006
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
Is NCT06584006 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Thymalfasin for and Recombinant Human Interleukin-2 Injections for hematological malignancy.
Treatment: Thymalfasin for · Recombinant Human Interleukin-2 Injections — To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Within 8 days after chemotherapy for lymphoma and within 14 days after chemotherapy for AML
Cannot have received: immunosuppressive treatment (cyclosporine, corticosteroids, ruxolitinib, JAK1/2 inhibitors)
Immunosuppressive treatment (such as cyclosporine, corticosteroids, ruxolitinib, JAK1/2 inhibitors, etc.) within the past 5 days
Cannot have received: allogeneic hematopoietic stem cell transplantation
Patients who have undergone allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
Tumor involvement in the bone marrow leading to hematopoietic suppression (neutrophils <1.0×10^9/L, HB<70g/L, PLT<50×10^9/L) [excluded]
Kidney function
Estimated creatinine clearance rate ≥ 30 mL/min.
Liver function
AST and ALT ≤ 3.0 x ULN. Bilirubin ≤ 1.5 x ULN.
Estimated creatinine clearance rate ≥ 30 mL/min. AST and ALT ≤ 3.0 x ULN. Bilirubin ≤ 1.5 x ULN. Tumor involvement in the bone marrow leading to hematopoietic suppression (neutrophils <1.0×10^9/L, HB<70g/L, PLT<50×10^9/L) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify